Further, procedures to biopsy tumors are not always feasible in HCC patients, and conventional clinical HCC biomarkers (AFP, AFP lectin fraction or des- γ- carboxy prothrombin) lack sensitivity and specificity. This evidence concerns the gene AFP and hepatocellular carcinoma.